Bessor Pharma is utilizing an innovative technology and business model for new drug development and value creation, with a focus on translating opportunities from university laboratories into proof-of-concept or clinical-ready packages for the pharma/biotech industry. The Company, which has unique skills, connectivity, and capital markets sophistication, is forging an ecosystem of academic and industry partners as key stakeholders facilitating translational R&D. Bessor is differentiated by its: aligned team with an unparalleled track record in drug development; operational progress; and unique collaborative partnerships fueling an innovative pipeline of highly needed drugs.
We have built a highly experienced and engaged leadership team and advisors that are committed to the translational development of our projects. Collectively, our team and advisors have been instrumental in the development of nearly 20 marketed drugs, including: Tykerb® (lapatinib), Gemzar® (gemcitabine), Coreg™ (carvedilol), and Corlopam® (fenoldopam).
Barry A. Berkowitz, PhD, Chairman of the Board of Directors and CEO
Allan M. Cohen, Esq, CPA, Vice President Licensing and General Counsel
Wallace Dairman, PhD, Vice President of Toxicology and Drug Development
Martin Hynes, PhD, Vice President Project Management and Quality Assurance
Satish Menon PhD, VP Biotechnology R&D
Robert Morgan, CPA, CFO
Eliot Ohlstein, PhD, VP Pharmacologic R&D
Eliot holds a BS in Pharmacy from the Massachusetts College of Pharmacy and a PhD in Pharmacology from the Tulane University School of Medicine.
Mark Roffman, PhD, Vice President of Drug Development and Regulatory Affairs